The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
Of the 16 patients in the trial, 44% showed an ASIA impairment scale conversion at six months, which served as the trial’s primary endpoint, passing the objective performance criterion of the study which was defined at a 25% AIS conversion rate.
All patients who showed an ASIA conversion at six months retained the condition at 12 months, though a single patient was “lost to follow up after the 6-month visit and was not assessed at a 12-month visit,” the company said. A total of 19 patients were implanted with the neuro-spinal scaffold, with three dying within two weeks of implantation.
“We will continue to follow this cohort of patients as they progress through their 24-month follow up visit and remain encouraged by the continued stability of the AIS conversion rate past the six-month primary endpoint visit,” prez & CEO Dr. Richard Toselli said in a press release.
Earlier this month, InVivo saw shares fall after the medical device maker missed expectations on Wall Street with its second quarter results.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!